Maninil (Glibenclamide)

Maninil, a sulfonylurea antidiabetic agent, is employed to improve glycaemic control in conditions related to insulin deficiency or resistance.

• Type 2 diabetes mellitus: improves overall blood glucose regulation.
• Inadequate response to diet and exercise in adults: provides additional glucose‑lowering effect.
• Need for oral antidiabetic therapy: serves as a sulfonylurea option when insulin is not yet required.

• Glibenclamide binds to the sulfonylurea receptor component of ATP‑sensitive potassium channels on pancreatic beta cells, causing channel closure. This depolarises the cell membrane, opens voltage‑dependent calcium channels, and triggers calcium influx, which promotes the exocytosis of insulin granules and raises circulating insulin levels.

Maninil may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Hypoglycaemia: feeling of weakness, sweating, or dizziness due to low blood sugar.
• Weight gain: modest increase in body weight with chronic use.
• Gastrointestinal discomfort: nausea, abdominal pain, or dyspepsia.
• Headache: mild to moderate intensity.
• Dizziness: transient light‑headedness.

Serious or Rare Side Effects

• Severe hypoglycaemia: confusion, loss of consciousness, or seizures.
• Allergic reactions: rash, pruritus, or angio‑edema.
• Blood dyscrasias: neutropenia or agranulocytosis.
• Hepatic dysfunction: elevated liver enzymes or hepatitis.
• Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating Maninil, several safety considerations should be observed.

• Blood glucose monitoring: regularly check levels to avoid hypoglycaemia.
• Renal impairment: dose may need adjustment or avoidance in severe dysfunction.
• Hepatic disease: use with caution and monitor liver function.
• Sulfonylurea hypersensitivity: discontinue if allergic signs appear.
• Concomitant medications: review for agents that may potentiate or diminish glucose‑lowering effects.
• Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Maninil can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

• Concurrent insulin or other sulfonylureas: risk of severe hypoglycaemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone): may increase glibenclamide plasma concentrations.
• MAO‑A inhibitors: can potentiate hypoglycaemic episodes.

Moderate Interactions (Monitor Closely)

• CYP2C9 inducers (e.g., rifampicin, carbamazepine): may reduce drug effectiveness.
• NSAIDs (e.g., ibuprofen, naproxen): can enhance hypoglycaemic risk.
• Thiazide diuretics: may augment glucose‑lowering effect.
• Beta‑blockers: can mask hypoglycaemia symptoms.